About

Company Profile & Milestones

Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline.

  • The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties.

  • The Company’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International.

  • In addition to Glassia, Kamada has a product line of nine other pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia.

  • Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed a pivotal Phase II/III clinical trials in Europe and has initiated Phase II clinical trials in the U.S.

  • Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.

  • Founded in 1990, Kamada is listed on NASDAQ since 2013 and Tel-Aviv stock exchange since 2005 (KMDA).
    Kamada’s headquarters is located in the Weizmann Science Park in Nes Ziona, Israel.

Kamada Milestones

1990
Kamada founded in Israel to develop and produce life-saving injectable pharmaceuticals
1991 mailstome
1991
First product - Albumin
1998
10 products are distributed in 15 countries
1999
New business strategy implemented: Focus on specialty products, Strategic partnerships and cooperation, US and EU market penetration, Increasing investment in R&D
2002
New development - liquid ready to use AAT
2004
Orphan Drug Designation for inhaled AAT in the US and EU
2005
Kamada becomes Israel’s first public biopharmaceutical company
2005
First patients are treated with Kamada’s AAT IV
2006
Strategic exclusive agreement with PARI for the eFlow device
2007
New patents issued for AAT
2008
Inhaled AAT: Successful completion of Phase II in CF patients, Successful completion of Phase II in Bronchiectasis patients
2009
AAT IV - Licensure and launching in Israel, Brazil and Russia
2010
AAT IV GLASSIA: FDA approval, Distribution and Technology license agreement with Baxalta (formerly Baxter) in US
2011
Diabetes Type I - Phase I / II initiation
2011
Partnership agreement with Kedrion for Rabies IG in the U.S
2011
Initiation of snake serum production for Israel MOH
2011
Kamada receive the Yitzhak Rabin National award for quality and excellence in the business sector
2012
Strategic distribution agreement with Chiesi for AAT Inhaled in Europe
2012
Successful phase I/II clinical trial results for Type-1 Diabetes
2013
AAT Inhaled - Completion of Phase II/III
2014
2nd extention of strategic distribusion agreement with Baxalta (formerly Baxter)
2015
Completion of US phase III Rabies lgG clinical trial
2015
U.S & EU orphan drug designation for AAT treat GVHD
2015
3rd extention of strategic distribution agreement with Baxalta
2016
Kamada’s Alpha-1 Antitrypsin Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform
2016
FDA Approval of Expanded Label for Self-Infusion of Glassia for AAT Deficiency
2017
Collaboration with Massachusetts General Hospital to Evaluate Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
2017
FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection
2017
Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients
2018
Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection